Methylphenidate Not Linked to Risk for Nonaffective Psychosis in ADHD

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Amazon Big Spring Sale - Up to 40% off

Medically reviewed by Carmen Pope, BPharm. Last updated on March 26, 2026.

via HealthDay

THURSDAY, March 26, 2026 -- For individuals with attention-deficit/hyperactivity disorder (ADHD), sustained treatment with methylphenidate is not associated with the risk for nonaffective psychosis, according to a study published online March 25 in JAMA Psychiatry.

Colm Healy, Ph.D., from the University of Edinburgh in the United Kingdom, and colleagues estimated the relationship between methylphenidate treatment and the risk for nonaffective psychosis in children and adolescents diagnosed with ADHD in a cohort study using data from multiple national Finnish registries for all 697,289 individuals born from 1987 to 1997.

The researchers found that 69.0 percent of the 3,956 individuals diagnosed with ADHD received methylphenidate at least once. Overall, 5.7 percent of individuals were diagnosed with nonaffective psychosis by a mean age of 22.16 years. Substantial variation was seen in hospital district prescribing propensity (first-year range, 0.07 to 0.30). In the overall ADHD sample, sustained methylphenidate treatment was not associated with the risk for nonaffective psychosis. A reduced risk for nonaffective psychosis was seen among individuals diagnosed in childhood (age younger than 13 years) in secondary analyses (three-year risk difference, −0.24; four-year risk difference, −0.21). For those diagnosed in adolescence, an insufficiently strong instrument precluded the same secondary analyses.

"The fact that early treatment was associated with a lower long-term risk of psychosis suggests these medications may do more than manage symptoms in childhood -- they may also have longer-term protective effects against severe mental illness, though this requires further research," lead author Ian Kelleher, M.D., Ph.D., also from the University of Edinburgh, said in a statement.

Two authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-27 02:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords